8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Jan 13, 2026·SEC
CG Oncology, Inc. Common stock(CGON)Earnings, Financials & Key Ratios
CGON•NASDAQ
$68.01
$5.74B mkt cap·Price updated May 6, 2026
AboutCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.Show more
- Revenue$4M+254.7%
- EBITDA-$189M-65.2%
- Net Income-$161M-82.9%
- EPS (Diluted)-2.08-47.5%
- Gross Margin-15.02%-115.0%
- EBITDA Margin-4686.36%+53.4%
- Operating Margin-4722.13%+53.1%
- Net Margin-3985.02%+48.4%
- ROE-21.67%-13.0%
- ROIC-23.77%+9.6%
- Debt/Equity0.01+2770.5%
CGON Key Insights
CG Oncology, Inc. Common stock (CGON) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 91 (top 9%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 23.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CGON Price & Volume
CG Oncology, Inc. Common stock (CGON) stock price & volume — 10-year historical chart
Loading chart...
CGON Growth Metrics
CG Oncology, Inc. Common stock (CGON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years176.56%
TTM254.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-82.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-61.24%
Return on Capital
10 Years-29.49%
5 Years-29.49%
3 Years-28.48%
Last Year-25.54%
CGON Recent Earnings
CG Oncology, Inc. Common stock (CGON) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/7 qtrs (29%)●Beat Revenue 3/7 qtrs (75%)
Q1 2026Latest
Feb 27, 2026EPS
$0.51
Est $0.61
+16.4%
Revenue
$2M
Est $450,538
+410.5%
Q4 2025
Nov 14, 2025EPS
$0.57
Est $0.56
-2.0%
Revenue
$2M
Est $59,364
+2706.4%
Q3 2025
Aug 8, 2025EPS
$0.54
Est $0.49
-10.2%
Revenue
—
Est $81,620
Q2 2025
May 13, 2025EPS
$0.45
Est $0.39
-15.4%
Revenue
$52,000
Est $118,170
-56.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 27, 2026 | $0.51vs $0.61+16.4% | $2Mvs $450,538+410.5% |
| Q4 2025 | Nov 14, 2025 | $0.57vs $0.56-2.0% | $2Mvs $59,364+2706.4% |
| Q3 2025 | Aug 8, 2025 | $0.54vs $0.49-10.2% | —vs $81,620 |
| Q2 2025 | May 13, 2025 | $0.45vs $0.39-15.4% | $52,000vs $118,170-56.0% |
Based on last 7 quarters of dataView full earnings history →
CGON Peer Comparison
CG Oncology, Inc. Common stock (CGON) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GRVY | 430.83M | 62.00 | 9.17 | 13.44% | 14.37% | 14.11% | ||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 JANX | 882.82M | 14.62 | -7.99 | -5.55% | -8.82% | -16.48% | 0.02 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 IMCR | 1.56B | 30.73 | -57.98 | 20% | -4.88% | -4.83% | 0.11 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 |
Compare CGON vs Peers
CG Oncology, Inc. Common stock (CGON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGON Income Statement
CG Oncology, Inc. Common stock (CGON) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Sales/Revenue | 10.36M | 191K | 204K | 1.14M | 4.04M |
| Revenue Growth % | - | -98.16% | 6.81% | 458.33% | 254.7% |
| Cost of Goods Sold | 10K | 15K | 0 | 0 | 4.65M |
| COGS % of Revenue | 0.1% | 7.85% | - | - | 115.02% |
| Gross Profit | 10.35M▲ 0% | 176K▼ 98.3% | 204K▲ 15.9% | 1.14M▲ 458.3% | -607K▼ 153.3% |
| Gross Margin % | 99.9% | 92.15% | 100% | 100% | -15.02% |
| Gross Profit Growth % | - | -98.3% | 15.91% | 458.33% | -153.29% |
| Operating Expenses | 22.95M | 35.42M | 55.65M | 115.81M | 190.17M |
| OpEx % of Revenue | 221.61% | 18545.55% | 27280.88% | 10167.25% | 4707.1% |
| Selling, General & Admin | 4.63M | 6.39M | 9.9M | 33.7M | 73.53M |
| SG&A % of Revenue | 44.75% | 3347.12% | 4853.43% | 2959% | 1819.95% |
| Research & Development | 18.32M | 29.03M | 45.75M | 82.1M | 116.64M |
| R&D % of Revenue | 176.86% | 15198.43% | 22427.45% | 7208.25% | 2887.15% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12.61M▲ 0% | -35.25M▼ 179.6% | -55.45M▼ 57.3% | -114.67M▼ 106.8% | -190.77M▼ 66.4% |
| Operating Margin % | -121.7% | -18453.4% | -27180.88% | -10067.25% | -4722.13% |
| Operating Income Growth % | - | -179.6% | -57.32% | -106.8% | -66.37% |
| EBITDA | -12.6M | -35.23M | -55.43M | -114.63M | -189.33M |
| EBITDA Margin % | -121.61% | -18445.55% | -27172.55% | -10064.44% | -4686.36% |
| EBITDA Growth % | - | -179.7% | -57.34% | -106.8% | -65.16% |
| D&A (Non-Cash Add-back) | 10K | 15K | 17K | 32K | 1.45M |
| EBIT | -12.39M | -35.25M | -55.45M | -114.67M | -161M |
| Net Interest Income | -451K | -1K | 6.9M | 26.62M | 0 |
| Interest Income | 0 | 0 | 6.9M | 26.62M | 0 |
| Interest Expense | 451K | 1K | 0 | 0 | 0 |
| Other Income/Expense | -233K | -197K | 6.84M | 26.63M | 29.78M |
| Pretax Income | -12.84M▲ 0% | -35.44M▼ 176.1% | -48.61M▼ 37.1% | -88.04M▼ 81.1% | -161M▼ 82.9% |
| Pretax Margin % | -123.95% | -18556.54% | -23826.96% | -7729.5% | -3985.02% |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -12.84M▲ 0% | -35.44M▼ 176.1% | -48.61M▼ 37.1% | -88.04M▼ 81.1% | -161M▼ 82.9% |
| Net Margin % | -123.95% | -18556.54% | -23826.96% | -7729.5% | -3985.02% |
| Net Income Growth % | - | -176.06% | -37.14% | -81.12% | -82.87% |
| Net Income (Continuing) | -12.84M | -35.44M | -48.61M | -88.04M | -161M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28▲ 0% | -0.66▼ 135.7% | -1.02▼ 54.5% | -1.41▼ 38.2% | -2.08▼ 47.5% |
| EPS Growth % | - | -135.71% | -54.55% | -38.24% | -47.52% |
| EPS (Basic) | -0.28 | -0.66 | -1.02 | -1.41 | -2.08 |
| Diluted Shares Outstanding | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M |
| Basic Shares Outstanding | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M |
| Dividend Payout Ratio | - | - | - | - | - |
CGON Balance Sheet
CG Oncology, Inc. Common stock (CGON) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Total Current Assets | 58.41M | 147.21M | 194.12M | 754.21M | 759.48M |
| Cash & Short-Term Investments | 53.61M | 143.48M | 187.67M | 742M | 742.15M |
| Cash Only | 53.61M | 88.14M | 8.27M | 257.07M | 32.49M |
| Short-Term Investments | 0 | 55.34M | 179.41M | 484.93M | 709.66M |
| Accounts Receivable | 2K | 303K | 92K | 781K | 688K |
| Days Sales Outstanding | 0.07 | 579.03 | 164.61 | 250.28 | 62.16 |
| Inventory | 0 | 0 | 0 | 0 | 1.56M |
| Days Inventory Outstanding | - | - | - | - | 122.92 |
| Other Current Assets | 4.8M | 3.42M | 6.36M | 11.43M | 15.07M |
| Total Non-Current Assets | 285K | 539K | 5.18M | 587K | 32.12M |
| Property, Plant & Equipment | 200K | 506K | 491K | 493K | 19.57M |
| Fixed Asset Turnover | 51.79x | 0.38x | 0.42x | 2.31x | 0.21x |
| Goodwill | 0 | 0 | 0 | 0 | 10.3M |
| Intangible Assets | 0 | 0 | 0 | 0 | 575K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 85K | 33K | 4.69M | 94K | 1.68M |
| Total Assets | 58.69M▲ 0% | 147.75M▲ 151.7% | 199.3M▲ 34.9% | 754.8M▲ 278.7% | 791.59M▲ 4.9% |
| Asset Turnover | 0.18x | 0.00x | 0.00x | 0.00x | 0.01x |
| Asset Growth % | - | 151.73% | 34.89% | 278.72% | 4.87% |
| Total Current Liabilities | 5.97M | 15.43M | 14.25M | 21.37M | 30.84M |
| Accounts Payable | 1M | 985K | 3.24M | 6.52M | 5.71M |
| Days Payables Outstanding | 36.61K | 23.97K | - | - | 448.81 |
| Short-Term Debt | 2.94M | 8.97M | 569K | 0 | 915K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.13M | 173K | 547K | 436K | 24.21M |
| Current Ratio | 9.78x | 9.54x | 13.62x | 35.30x | 24.63x |
| Quick Ratio | 9.78x | 9.54x | 13.62x | 35.30x | 24.58x |
| Cash Conversion Cycle | - | - | - | - | -263.73 |
| Total Non-Current Liabilities | 12.46M | 7.14M | 257K | 52K | 8.15M |
| Long-Term Debt | 12.06M | 6.53M | 0 | 0 | 6.11M |
| Capital Lease Obligations | 50K | 257K | 244K | 52K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 307K |
| Other Non-Current Liabilities | 351K | 352K | 13K | 0 | 1.74M |
| Total Liabilities | 18.44M | 22.57M | 14.51M | 21.42M | 38.99M |
| Total Debt | 15.13M | 15.94M | 1.03M | 238K | 7.02M |
| Net Debt | -38.48M | -72.2M | -7.24M | -256.83M | -25.47M |
| Debt / Equity | 0.38x | 0.13x | 0.01x | 0.00x | 0.01x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -27.47x | -35246.00x | - | - | - |
| Total Equity | 40.25M▲ 0% | 125.18M▲ 211.0% | 184.79M▲ 47.6% | 733.38M▲ 296.9% | 752.6M▲ 2.6% |
| Equity Growth % | - | 210.98% | 47.62% | 296.87% | 2.62% |
| Book Value per Share | 0.60 | 1.88 | 2.77 | 11.73 | 9.74 |
| Total Shareholders' Equity | 40.25M | 125.18M | 184.79M | 733.38M | 752.6M |
| Common Stock | 0 | 0 | 0 | 8K | 8K |
| Retained Earnings | -45.89M | -81.33M | -129.94M | -217.98M | -378.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
CGON Cash Flow Statement
CG Oncology, Inc. Common stock (CGON) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Cash from Operations | -13.65M | -29.8M | -45.68M | -78.71M | -132.35M |
| Operating CF Margin % | -131.82% | -15604.19% | -22391.67% | -6910.71% | -3275.89% |
| Operating CF Growth % | - | -118.28% | -53.26% | -72.32% | -68.14% |
| Net Income | -12.84M | -35.44M | -48.61M | -88.04M | -161M |
| Depreciation & Amortization | 10K | 15K | 17K | 32K | 1.45M |
| Stock-Based Compensation | 1.11M | 676K | 1.53M | 11.4M | 26.68M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 30K | 509K | -2.06M | -5.01M | -1.75M |
| Working Capital Changes | -1.97M | 4.44M | 3.44M | 2.91M | 2.28M |
| Change in Receivables | 0 | 0 | 0 | -689K | -320K |
| Change in Inventory | 0 | 0 | 0 | 0 | -444K |
| Change in Payables | 578K | -18K | 2.01M | 3.27M | -1.64M |
| Cash from Investing | -97K | -55.35M | -121.19M | -300.76M | -245.82M |
| Capital Expenditures | -97K | -14K | 0 | -234K | -134K |
| CapEx % of Revenue | 0.94% | 7.33% | - | 20.54% | 3.32% |
| Acquisitions | 0 | 0 | 0 | 0 | -21.97M |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 15.45M | 119.69M | 87M | 628.28M | 153.59M |
| Debt Issued (Net) | 15.2M | 0 | -16.29M | -365K | 0 |
| Equity Issued (Net) | 245K | 119.69M | 104.63M | 629.47M | 153.59M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -1.34M | -825K | 0 |
| Net Change in Cash | 1.7M▲ 0% | 34.54M▲ 1937.5% | -79.88M▼ 331.3% | 248.8M▲ 411.5% | -224.58M▼ 190.3% |
| Free Cash Flow | -13.75M▲ 0% | -29.82M▼ 116.8% | -45.68M▼ 53.2% | -78.95M▼ 72.8% | -132.48M▼ 67.8% |
| FCF Margin % | -132.76% | -15611.52% | -22391.67% | -6931.26% | -3279.21% |
| FCF Growth % | - | -116.84% | -53.19% | -72.83% | -67.81% |
| FCF per Share | -0.21 | -0.45 | -0.69 | -1.26 | -1.71 |
| FCF Conversion (FCF/Net Income) | 1.06x | 0.84x | 0.94x | 0.89x | 0.82x |
| Interest Paid | 0 | 0 | 376K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
CGON Key Ratios
CG Oncology, Inc. Common stock (CGON) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -31.9% | -42.85% | -31.36% | -19.18% | -21.67% |
| Return on Invested Capital (ROIC) | - | -96.56% | -36.08% | -26.3% | -23.77% |
| Gross Margin | 99.9% | 92.15% | 100% | 100% | -15.02% |
| Net Margin | -123.95% | -18556.54% | -23826.96% | -7729.5% | -3985.02% |
| Debt / Equity | 0.38x | 0.13x | 0.01x | 0.00x | 0.01x |
| Interest Coverage | -27.47x | -35246.00x | - | - | - |
| FCF Conversion | 1.06x | 0.84x | 0.94x | 0.89x | 0.82x |
| Revenue Growth | - | -98.16% | 6.81% | 458.33% | 254.7% |
CGON SEC Filings & Documents
CG Oncology, Inc. Common stock (CGON) SEC filings — annual & quarterly reports (10-K, 10-Q)
CGON Frequently Asked Questions
CG Oncology, Inc. Common stock (CGON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CG Oncology, Inc. Common stock (CGON) reported $4.0M in revenue for fiscal year 2025. This represents a 61% decrease from $10.4M in 2021.
CG Oncology, Inc. Common stock (CGON) grew revenue by 254.7% over the past year. This is strong growth.
CG Oncology, Inc. Common stock (CGON) reported a net loss of $161.0M for fiscal year 2025.
Dividend & Returns
CG Oncology, Inc. Common stock (CGON) has a return on equity (ROE) of -21.7%. Negative ROE indicates the company is unprofitable.
CG Oncology, Inc. Common stock (CGON) had negative free cash flow of $132.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More CGON
CG Oncology, Inc. Common stock (CGON) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates